Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 86 от 154

Предстои набиране Фаза 3

Study of Serine Supplementation to Protect Vision in MacTel

Macular Telangiectasia Type 2 (MacTel)

The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2. The main questions it aims to answer are: * Does serine slow the progression of MacTel? * Is long-term serine supplementation safe in people with MacTel? Researchers will compare serine to a placebo (a look-alike substance that contains no drug) to see if serine works to slow the progression of MacTel. Participants will: * Take serine or a placebo twice a day for 24 months * Visit the clinic once every 6 months for eye exam, eye imaging and blood tests * Keep a diary of their symptoms, missed doses, and changes in medications

Начало: 01.09.2026 Край: 01.02.2030 Възраст: от 18 г. Лечение

Australia, Germany, Netherlands +2 The Lowy Medical Research Institute Limited NCT07342439

Предстои набиране Фаза 2

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Obesity and Overweight

A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

Начало: 15.08.2026 Край: 15.12.2027 Възраст: 19–80 г. Лечение

Australia, New Zealand, United States Biomed Industries, Inc. NCT06732245

Предстои набиране Фаза 2/3

Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

RETT Syndrome With Proven MECP2 Mutation Rett Syndrome

The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design. RTT is a devastating rare genetic condition affecting females and involves debilitating physical and intellectual symptoms. NTI164 is an oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT, autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicatric syndrome (PANS). A Phase I/II clinical trial of NTI164 in RTT (FENRTT1/NTIRTT1) showed NTI164 is safe in this population and significantly improved overall clinical severity of illness, as well as core RTT symptoms, including anxiety, mental alertness, communication skills, socialisation/eye contact, and attentiveness. The FENRTT2 study will investigate NTI164 in a larger number of patients, and compare NTI164 to a placebo control. Research tests on patient blood will also be included to further investigate how NTI164 works in the body.

Начало: 01.07.2026 Край: 01.10.2028 Възраст: 4–25 г. Лечение

Australia Fenix Innovation Group NCT07257978

Предстои набиране

A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure

Atrial Arrhythmia Intracardiac Echocardiography

A first-in-human prospective data collection study including subjects who are planned to undergo an ablation procedure for any atrial arrhythmia as per medical judgement and the site's standard practice, represents the most viable means to collect human anatomy ICE images for the purpose of software development.

Начало: 01.07.2026 Край: 31.01.2027 Възраст: от 18 г. Диагностика

Australia, Croatia, Czechia +5 Boston Scientific Corporation NCT07353710

Предстои набиране Фаза 3

NTI164 in Autism Spectrum Disorder

Autism Autism Spectrum Disorder Autism Disorder

This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal cannabis plant extract on core and associated ASD symptoms over placebo. Participants will be randomly allocated to either NTI164 or placebo at a 1:1 ratio and blood samples will be collected and surveys completed at baseline and Week 16. This study will expand efficacy and safety data of NTI164 and provide additional mechanism of action data of NTI164 in this patient cohort.

Начало: 01.07.2026 Край: 01.07.2030 Възраст: 6–25 г. Лечение

Australia Fenix Innovation Group NCT07257939

Предстои набиране

Is Density Spectral Array Display Along With Bispectral Index Superior to the Display of Bispectral Index Alone

Awareness During General Anesthesia

A study to evaluate the use of density spectral array display in comparison with Bispectral index in a clinical setting.

Начало: 30.06.2026 Край: 01.12.2029 Възраст: от 65 г.

Australia The University of Queensland NCT07232160

Предстои набиране Фаза 3

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

Systemic Sclerosis

Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day. Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 09.06.2026 Край: 17.03.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +37 Boehringer Ingelheim NCT07497087

Предстои набиране Фаза 3

A Phase III Randomised Clinical Trial of Ultrasound Groin Monitoring Versus Groin Lymph Node Dissection to De-Escalate the Extent of Surgery in Vulvar Cancer

Vulvar Cancer Stage I Vulvar Cancer Stage II Lymph Node Metastasis Groin Node +1

This study is a phase III, open label, multicentre, three-group, randomised clinical trial. The primary aim of this study is to determine whether intensive groin ultrasound monitoring (1) is effective and safe to replace invasive groin lymph node dissection (LND) to manage vulvar cancer, (2) decreases the morbidity associated with vulvar cancer surgery, and (3) is cost effective.

Начало: 01.06.2026 Край: 31.12.2035 Възраст: от 18 г. Лечение

Australia Queensland Centre for Gynaecological Cancer NCT06476639

Предстои набиране

Describing the Effect of Familiar Song on Arousal and Awareness for Children With Disorders of Consciousness (DoC)

Disorder of Consciousness Acquired Brain Injury

The goal of this clinical trial is to compare the effect of live music therapy and recorded music on recovery of consciousness in children aged 1 to 18 years who have a disorder of consciousness (DoC) after a severe brain injury. Researchers also want to learn how children respond during music and noise, whether early responses to music are linked to recovery at 6 months, and how parents experience music therapy during their child's hospital stay at The Royal Children's Hospital (RCH) in Melbourne. Participants will: * Take part in a 10-day study period while in hospital. On 8 of the 10 days, they will receive either live or recorded familiar music in random order. Their level of consciousness will be measured before and after each session using a simple behavioural checklist. On the other 2 days, they will take part in video-recorded sessions to compare behavioural responses during live music, recorded music, and white noise. Videos will help capture small changes in movement, eye gaze, or facial expression. * Have their level of consciousness checked again at 6 months after injury to see if early responses relate to later recovery. Parents and caregivers will be invited to take part in an interview about their experiences and observations of music therapy with their child. This study will help researchers understand whether live music therapy provides benefits beyond recorded music and will guide how music therapy is best used to support children and families during recovery from severe brain injury.

Начало: 01.06.2026 Край: 30.11.2028 Възраст: 1–18 г. Лечение

Australia Murdoch Childrens Research Institute NCT07209657

Предстои набиране Фаза 2

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

Cancer of Unknown Primary

The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).

Начало: 01.06.2026 Край: 01.06.2030 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT07434180

Предстои набиране Фаза 1

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Elevated LDL-C and High Cholesterol

STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.

Начало: 01.06.2026 Край: 30.12.2028 Възраст: 18–70 г. Лечение

Australia Monash University NCT07428473

Предстои набиране Фаза 1

ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain

Facet Joint Pain

The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.

Начало: 01.06.2026 Край: 30.04.2027 Възраст: от 18 г. Лечение

Australia Interventional AnalgesiX Inc. NCT07520240

Предстои набиране Фаза 1

A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )

Lymphoma, Non-Hodgkin B-cell Lymphoma Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell lymphoma.

Начало: 01.06.2026 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, Canada, Denmark +8 Eli Lilly and Company NCT07101328

Предстои набиране Фаза 4

Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course'

Urinary Tract Infection Cellulitis Respiratory Tract Infections Lymphadenitis

The aim of the StopStop@HITH study is to see if stopping antibiotics when symptoms stop is as good as finishing the course of antibiotics. The study will enrol children at the Royal Children's Hospital who are prescribed oral antibiotics after completing a course of intravenous (IV) antibiotics for the treatment of cellulitis, urinary tract infection (UTI), lower respiratory tract infection (LRTI) and lymphadenitis. The aims of the study are: * To determine if oral antibiotics can be safely stopped once symptoms stop in children with cellulitis (who have completed a course of IV antibiotics). * To assess feasibility of a larger study of other common infections across multiple hospitals. The participants parent/guardian will complete a daily symptom tracker for the duration of the prescribed oral antibiotic course and attend a telehealth appointment with the study team once the participants symptoms have resolved. There are additional follow up surveys at day 14, day 28 and day 180.

Начало: 01.06.2026 Край: 01.06.2028 Възраст: 1–17 г. Лечение

Australia Murdoch Childrens Research Institute NCT07532941

Предстои набиране Фаза 1

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

UC - Ulcerative Colitis

This Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and cytokine profiles of LYNC-101 for Injection in healthy adult participants. The study consists of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study. In Part 1, participants will receive a single intravenous infusion of LYNC-101 for Injection or placebo across sequential ascending dose cohorts. In Part 2, participants will receive intravenous infusions of LYNC-101 for Injection or placebo once every 3 weeks for a total of 3 doses across sequential ascending dose cohorts.

Начало: 25.05.2026 Край: 11.04.2027 Възраст: 18–60 г. Лечение

Australia LyncBio Therapeutics Co., Ltd. NCT07505030

Предстои набиране Фаза 1

A Study of HS-20136-2 in Healthy Participants

Healthy

This is a randomized, double-blind,placebo-controlled phase I clinical study.The main purpose is to assess the safety and tolerability of single subcutaneous administration of HS-20136-2 injection in healthy participants.

Начало: 15.05.2026 Край: 31.12.2026 Възраст: 18–65 г. Фундаментална наука

Australia Jiangsu Hansoh Pharmaceutical Co., Ltd. NCT07483437

Предстои набиране Фаза 2

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Lung Cancer, Non-squamous, Non-small Cell

This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study is to find out how well a medicine called zongertinib is tolerated in people with this type of lung cancer, when combined with chemotherapy, with or without pembrolizumab. Zongertinib works by targeting and blocking HER2, a protein involved in cancer cell growth. Participants are put into two groups randomly, which means by chance. One group gets zongertinib tablets combined with platinum-based chemotherapy. The other group gets the same treatment plus an additional medicine called pembrolizumab. Chemotherapy and pembrolizumab are given as an infusion into a vein. Participants take zongertinib by mouth once a day, while chemotherapy is given every 3 weeks for up to 3 months, followed by maintenance treatment for up to 2 years. Pembrolizumab is given every 3 weeks for up to 2 years. This study does not have a fixed duration. Participants can receive some of the study treatments for up to about 2 years and may continue to take zongertinib as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. Doctors regularly check the size of the tumor and whether it has spread. They also monitor participants' health and take note of any unwanted effects.

Начало: 08.05.2026 Край: 25.08.2029 Възраст: от 18 г. Лечение

Australia, China, France +4 Boehringer Ingelheim NCT07486817

Предстои набиране Фаза 1

To Test a New Drug (LCFA-01) for Safety and PK in Healthy Adults for Bacterial Vaginosis Infection.

Bacterial Vaginosis Treatment

This study is being done to check how safe and comfortable LCFA-01 is when used inside the vagina. LCFA-01 is a natural product that contains oleic acid, and it comes as a soft gel capsule that participants will place in the vagina using their fingers. The main purpose of the study is to make sure the product is safe and does not cause any problems or discomfort. The study will also measure how much of the product stays in the vagina and whether any of it enters the bloodstream. This helps researchers understand how the body absorbs and handles the product. Finally, the study will also look at early signs of how the product might affect the natural bacteria in the vagina. In the future, LCFA-01 may be used to treat bacterial vaginosis (BV).

Начало: 06.05.2026 Край: 31.07.2026 Възраст: 18–40 г. Лечение

Australia Massachusetts General Hospital NCT07514416

Предстои набиране Фаза 1

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

Huntington's Disease

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

Начало: 05.05.2026 Край: 30.11.2027 Възраст: 21–70 г. Лечение

New Zealand Sarepta Therapeutics, Inc. NCT07536061

Предстои набиране Фаза 2/3

To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease

Agitation in Dementia

This study tests a medication called dronabinol in people with Alzheimer's disease. First, participants go through up to 4 weeks of screening. Then, over 2 weeks, the dose of the study drug is slowly increased. For the next 10 weeks, participants stay on either dronabinol or a placebo. After finishing this part of the study, participants can join a 6-month extension where everyone receives dronabinol. Those already on the drug stay on their same dose, while those who were on placebo gradually increase their dose over 2 weeks. All participants take dronabinol for the rest of the extension, then complete a final safety check 4 weeks after stopping the medication. Usual medical treatments are continued throughout the study.

Начало: 01.05.2026 Край: 01.08.2028 Възраст: 50–90 г. Превенция

Australia Benuvia Therapeutics Inc. NCT07422311

1 … 84 85 86 87 88 … 154